BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease
in Acute Myeloid Leukemia 2 BLAST MRD AML-2: A randomized Phase 2 Study of the
Venetoclax, Azacitidine, and Pembrolizumab VAP Versus Venetoclax and Azacitidine as First
Line Therapy in Older Patients with Acute Myeloid Leukemia AML who are Ineligible or who
Refuse Intensive Chemotherapy
Randomized Phase II Trial of Fulvestrant or Exemestane With or Without Ribociclib After Progression on Anti-Estrogen Therapy Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer MAINTAIN
A Phase II Study of 9-ING-41 GSK-3? Combined with Retifanlimab plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients with Advanced Pancreatic Adenocarcinoma
NCI-COG Pediatric MATCH Molecular Analysis for Therapy Choice - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for
Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
An Open-Label, Multicenter, Phase IB/II Study of Rebastinib DCC-2036 in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors